Announced details
CG923308 IC50 values: 15 nM in OVCAR3, 0.9 nM in MKN1 and 1.8 nM in HCC1599; over 500 nM in normal HEK293T cells and hPBMCs
CG923308 DC50 values in MKN1: <0.3 nM for CDK2, 0.5 nM for Cyclin E1 and <0.3 nM for Cyclin E2
740 global employees (Gyre Therapeutics)
Gyre Therapeutics, Inc. is the Company’s consolidated subsidiary. Cullgen Inc. is identified as a subsidiary of Gyre.
San Diego, California, United States, Beijing, China, Shanghai, China
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Gyre’s annual report filed with the U.S. Securities and Exchange Commission (SEC) (Form 10-K)
American Cancer Society（ACS）
TCGA database and cBioPortal analysis
Turner NC (2019) J Clin Oncol
Herrera-Abreu MT (2016) Cancer Research
Costa C (2020) Cancer Discovery
Freeman-Cook (2021) Cancer Cell
Wander SA (2020) Cancer Discovery
Howlader (2014) Journal of the National Cancer Institute
Gehrchen ML et al. (2024) BJC Reports
| Item | Details |
|---|---|
| Names of Products / Services Covered | CG923308, Aisu Ruilui, a pirfenidone product, Hydronidone (F351), CG620953, F528 |
| Relationship with the Company | Gyre Therapeutics, Inc. is the Company’s consolidated subsidiary. Cullgen Inc. is identified as a subsidiary of Gyre. |
| Launch date | 15 May 2026 (presentation at a scientific conference; actual) |
| Applicable area | Fibrosis, Inflammatory diseases, Cancer, MASH-associated liver fibrosis, Solid tumors, CCNE1-amplified solid tumors, CDK4/6 inhibitor-resistant HR+/HER2− breast cancer |
| Location | San Diego, California, United States, Beijing, China, Shanghai, China |
| Quantitative Effects | CG923308 IC50 values: 15 nM in OVCAR3, 0.9 nM in MKN1 and 1.8 nM in HCC1599; over 500 nM in normal HEK293T cells and hPBMCs, CG923308 DC50 values in MKN1: <0.3 nM for CDK2, 0.5 nM for Cyclin E1 and <0.3 nM for Cyclin E2 |
| Usage history | 740 global employees (Gyre Therapeutics) |
| Source | Gyre’s annual report filed with the U.S. Securities and Exchange Commission (SEC) (Form 10-K), American Cancer Society（ACS）, TCGA database and cBioPortal analysis, Turner NC (2019) J Clin Oncol, Herrera-Abreu MT (2016) Cancer Research, Costa C (2020) Cancer Discovery, Freeman-Cook (2021) Cancer Cell, Wander SA (2020) Cancer Discovery, Howlader (2014) Journal of the National Cancer Institute, Gehrchen ML et al. (2024) BJC Reports |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide the presentation materials to investors. If there is any discrepancy between the reference translation and the original text, the original text takes precedence.